A final analysis of the data from the ALUR study confirmed the superiority of alectinib compared with chemotherapy in patients with crizotinib-resistant ALK-positive NSCLC.
Results from this analysis showed that approximately 25% of younger African-Americans at high risk of lung cancer would be missed using USPSTF screening criteria.
Autologous activated killer T cells and dendritic cells from regional lymph nodes were infused with or without chemotherapy in the adjuvant setting.
Treatment-related adverse effects of the sintilimab-anlotinib combination regimen included hand-foot syndrome and hyponatremia.
There are few observational studies examining patients with aNSCLC who have been treated with immune checkpoint inhibitor therapy.
There are few clinical trials examining immune checkpoint inhibitor therapy in advanced NSCLC that enroll a high percentage of Asian patients.
IBM Watson Health’s Clinical Trials Matching (CTM) is an artificial intelligence system that can increase the efficiency of patient screening and recruitment into clinical trials.
One goal of the INTEGRAL initiative is to incorporate validated biomarkers of lung cancer risk into lung cancer CT screening protocols.
Many immunotherapy-based combinations are being studied in NSCLC, with TMB emerging as a potential predictive biomarker.
Tislelizumab, an anti-PD-1 antibody, demonstrated antitumor activity in phase 1 and phase 2 trials of Chinese patients with advanced lung cancers.
Please login or register first to view this content.
